Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
1.53 ^USD	+5.52%		-8.38%	-70.29%

05-15	Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	CI
05-14	Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Reviva Pharmaceuticals Holdings, Inc. Provides Preliminary Earnings Guidance for the Quarter Ended March 31, 2021

May 10, 2021 at 09:31 am

Reviva Pharmaceuticals Holdings, Inc. provided preliminary earnings guidance for the quarter ended March 31, 2021. For the quarter, the company's net operating loss is expected to be approximately $1.9 million.

Latest news about Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	05-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Reviva Pharmaceuticals Holdings, Inc. to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference	05-13	CI
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	04-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	11-20	MT
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding	11-19	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	11-16	MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	11-16	MT
Sector Update: Health Care	11-16	MT
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall	11-16	MT
Reviva Pharmaceuticals to Seek Acquisitions	11-16	CI
Reviva Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.999942 million in funding	11-14	CI
Reviva Pharmaceuticals Holdings Q3 Loss Widens	11-14	MT
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
HC Wainwright Raises Reviva Pharmaceuticals' Price Target to $20 From $10, Keeps Buy Rating	23-10-31	MT
Sector Update: Health Care Stocks Gain Late Afternoon	23-10-30	MT
Sector Update: Health Care	23-10-30	MT
Reviva Shares Surge After Late-Stage Schizophrenia Trial Meets Primary Endpoint	23-10-30	MT
Top Midday Gainers	23-10-30	MT
Reviva Pharmaceuticals Says Phase 3 RECOVER Trial of Brilaroxazine in Adults With Schizophrenia Meets Primary Endpoint	23-10-30	MT
Reviva Pharma's schizophrenia drug succeeds in late-stage study	23-10-30	RE
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	23-10-30	CI
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday	23-09-25	MT
Reviva Pharmaceuticals Says Last Patient Evaluated in Phase 3 Trial of Brilaroxazine to Treat Schizophrenia	23-09-25	MT

Chart Reviva Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Reviva Pharmaceuticals Holdings, Inc.

More charts

Company Profile

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Companyâs pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimerâs disease (BPSD), and Parkinsonâs disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Lytham Partners Spring Investor Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.53 USD

Average target price

14.75 USD

Spread / Average Target

+864.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REVIVA PHARMACEUTICALS HOLDINGS, INC.	-70.29%	42.72M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research